AL
ALPMY.US Astellas Pharma Inc
- Market cap
- USD 30.2B
- P/E
- 12.4x
- P/B
- 2.37x
- ROE
- 24.6%
- Dividend yield
- 2.94%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is ALPMY.US undervalued?
Graham numberALPMY.US trades 14.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Astellas Pharma Inc fundamental analysis
No fundamental analysis for Astellas Pharma Inc yet.
Astellas Pharma Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Astellas Pharma Inc
Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associ…
Full company profileAstellas Pharma Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Astellas Pharma Inc annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.31T | 1.30T | 1.31T | 1.30T | 1.25T | 1.30T | 1.52T | 1.60T | 1.91T | 2.27T | 2.56T |
| Gross Profit | 955B | 970B | 979B | 1.00T | 980B | 1.01T | 1.19T | 1.31T | 1.56T | 1.69T | 1.92T |
| Operating Income | 276B | 271B | 280B | 279B | 136B | 156B | 285B | 25.5B | 41.0B | 445B | 712B |
| EBITDA | 348B | 285B | 314B | 315B | 220B | 242B | 247B | 195B | 248B | 640B | 912B |
| Net Income | 219B | 165B | 222B | 195B | 121B | 124B | 98.7B | 17.0B | 50.7B | 309B | 487B |
| EPS | 104 | 81 | 115 | 104 | 65 | 67 | 54 | 9.47 | 28 | 172 | 270 |
| Balance Sheet | |||||||||||
| Total Assets | 1.81T | 1.86T | 1.90T | 2.32T | 2.27T | 2.33T | 2.46T | 3.57T | 3.34T | 3.58T | 3.53T |
| Total Liabilities | 542B | 590B | 639B | 1.03T | 888B | 872B | 949B | 1.97T | 1.83T | 1.74T | 1.54T |
| Shareholders' Equity | 1.27T | 1.27T | 1.26T | 1.29T | 1.39T | 1.46T | 1.51T | 1.60T | 1.51T | 1.84T | 1.98T |
| Cash & Short-term Investments | 341B | 332B | 311B | 328B | 326B | 337B | 397B | 364B | 218B | 283B | 238B |
| Total Debt | 1.64B | 1.35B | 1.20B | 398B | 278B | 213B | 200B | 920B | 831B | 247B | 425B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 237B | 314B | 261B | 222B | 307B | 257B | 328B | 172B | 195B | 600B | 545B |
| Capital Expenditure | 48.6B | 40.3B | 52.1B | 77.9B | 77.4B | 76.4B | 88.5B | 82.5B | 57.3B | 61.2B | 49.7B |
| Free Cash Flow | 189B | 274B | 209B | 144B | 229B | 181B | 239B | 90.0B | 137B | 539B | 495B |
| Ratios | |||||||||||
| ROE | 17.2% | 13.0% | 17.7% | 15.2% | 8.7% | 8.5% | 6.5% | 1.1% | 3.4% | 16.8% | 24.6% |
| ROA | 12.1% | 8.9% | 11.7% | 8.4% | 5.3% | 5.3% | 4.0% | 0.5% | 1.5% | 8.6% | 13.8% |
| Net Profit Margin | 16.7% | 12.7% | 17.0% | 15.0% | 9.7% | 9.6% | 6.5% | 1.1% | 2.7% | 13.6% | 19.0% |
| Debt to Equity | 0.00x | 0.00x | 0.00x | 0.31x | 0.20x | 0.15x | 0.13x | 0.58x | 0.55x | 0.13x | 0.21x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Astellas Pharma Inc dividends
- Dividend yield
- 2.94%
- Forward dividend
- 0.50 USD
- Payout ratio
- 46.7%
- Ex-dividend date
- Mar 31, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | JPY 144B | 80 | 46.7% |
| 2025 | JPY 129B | 72 | 254.2% |
| 2024 | JPY 117B | 65 | 684.4% |
| 2023 | JPY 100B | 55 | 101.7% |
| 2022 | JPY 85.2B | 46 | 68.7% |
| 2021 | JPY 76.2B | 41 | 63.2% |
| 2020 | JPY 73.5B | 39 | 37.6% |
| 2019 | JPY 72.1B | 37 | 32.4% |
| 2018 | JPY 71.6B | 35 | 43.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 125:100 on Apr 2, 2014.
Who owns Astellas Pharma Inc
- Insiders 0.00%
- Institutions 0.03%
- Public & others 99.98%
- Shares outstanding 1.79B
- Free float 1.79B
Astellas Pharma Inc company profile
- Company name
- Astellas Pharma Inc
- Ticker
- ALPMY.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 14,099
- Fiscal year end
- March
- Address
- 2-5-1, Nihonbashi-Honcho, Chuo, Japan, 103-8411
- Phone
- 81 3 3244 3000
- Website
- astellas.com
About Astellas Pharma Inc
Astellas Pharma Inc. engages in the research, development, manufacture, sale, and supply of pharmaceuticals in Japan and internationally. The company offers XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for acute myeloid leukemia; VYLOY, a treatment for gastric adenocarcinoma and esophagogastric junction adenocarcinoma; and PADCEV, a treatment for patients with metastatic urothelial carcinoma. It also provides VEOZAH, a treatment for vasomotor symptoms associated with menopause; IZERVAY, a treatment for age-related macular degeneration with geographic atrophy; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf, an immunosuppressant. It offers its products to oncology, ophthalmology, urology, immunology, and women's health areas. The company was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005. Astellas Pharma Inc. was founded in 1923 and is headquartered in Chuo, Japan.
Astellas Pharma Inc management
10- Mr. Naoki Okamura BScPresident, CEO & Representative Director · born 1962
- Mr. Katsuyoshi SugitaExecutive VP, Chief People Officer & Representative Director · born 1967
- Mr. Atsushi KitamuraChief Financial Officer
- Nobue YasudaGeneral Manager of Finance & Accounting Department
- Mr. Yoshitsugu Shitaka Ph.D.Chief Scientific Officer & Senior Managing Executive Officer
- Ms. Nobuko KatoChief Communications & Investor Relations Officer
- Ms. Nahrin MarinoGeneral Counsel and Chief Ethics & Compliance Officer
- Mr. Nobuaki TanakaPresident of Japan Commercial & Senior Corporate Executive
- Mr. Jun Kono M.B.A.Senior Executive Officer & Head of Japan Commercial
- Ms. Leticia Delgado-HerreraVP and Rx+ M&D Head